India Exchange Filings

NATCO Pharma Q2 FY27 Earnings and Board Meeting Highlights

Natco Pharma Ltd reports Q2 FY27 revenue of ₹1,019.4 crore and approves ₹1.25/share interim dividend

  • Revenue rose 28.4% QoQ and fell 30.3% YoY; net profit was ₹202.6 crore, down 1.9% QoQ and 60.9% YoY.
  • EBITDA margin was 30.4%, versus 30.9% in Q1 FY27 and 46.4% in Q2 FY26.
  • Record date for the second interim dividend is 19 November 2026; auditors issued an unmodified limited review report.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.